Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The Cholesterol Synthesis Pathway as a Novel Therapeutic Target for Glioblastoma
EF 2017-18
Résumé
Glioblastoma is the most common and lethal form of brain cancer. The current standard of care consists of non-specific treatments and only extend the survival rate of patients by a small fraction. The average patient survival following diagnosis is 18 months with less than 30% of patients surviving 24 months. Only few designed therapeutics targeting Glioblastoma have been developed in recent years and have made it into clinical trials. However, the targeted therapeutics have not been successful and the treatment for Glioblastoma has not appreciably improved over the past 50 years. It is imperative to discover novel therapeutic targets for this type of cancer.In this project, I will investigate into a cell signaling pathway that is recently shown to be essential for Glioblastoma cells to survive. I hypothesize that this pathway can be exploited for therapeutic designs and will conduct drug screening to discover novel drug candidates to inhibit the growth of these brain cancer cells. In addition, my research project will also help address some of the questions that have not been answer in the field and potentially be a stepping stone for developing new treatment strategies against Glioblastoma.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386661
Name
Yang De Hua
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Cholesterol Synthesis Pathway as a Novel Therapeutic Target for Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cell Signalling; Cholesterol Synthesis; Crispr; Glioblastoma; Lc/Ms
Abstract
Glioblastoma is the most common and lethal form of brain cancer. The current standard of care consists of non-specific treatments and only extend the survival rate of patients by a small fraction. The average patient survival following diagnosis is 18 months with less than 30% of patients surviving 24 months. Only few designed therapeutics targeting Glioblastoma have been developed in recent years and have made it into clinical trials. However, the targeted therapeutics have not been successful and the treatment for Glioblastoma has not appreciably improved over the past 50 years. It is imperative to discover novel therapeutic targets for this type of cancer.In this project, I will investigate into a cell signaling pathway that is recently shown to be essential for Glioblastoma cells to survive. I hypothesize that this pathway can be exploited for therapeutic designs and will conduct drug screening to discover novel drug candidates to inhibit the growth of these brain cancer cells. In addition, my research project will also help address some of the questions that have not been answer in the field and potentially be a stepping stone for developing new treatment strategies against Glioblastoma.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yang, De Hua
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~